Seladelpar

Seladelpar

Clinical data
Other names	MBX-8025; RWJ-800025
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
CAS Number	851528-79-5
PubChem CID	11236126
DrugBank	DB12390
ChemSpider	9411171
UNII	7C00L34NB9
KEGG	D11256
ChEMBL	ChEMBL230158
Chemical and physical data
Formula	C21H23F3O5S
Molar mass	444.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
InChI InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1 Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N

Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.

See also

• Elafibranor
• GW501516
• Peroxisome proliferator-activated receptor

External links

• Seladelpar - AdisInsight